Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFP4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,955
Award facts
- Contract value 100% obligated
- $57,954.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $57,954.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Nucala 100 mg/ml syringes, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without set-aside designation, demonstrating competitive capability in unrestricted federal procurement. The delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
As a critical supplier within the federal pharmaceutical supply chain since its registration in the System for Award Management in 2001, DMS Pharmaceutical Group maintains an extensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's established performance across multiple therapeutic categories and delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of military healthcare operations. This delivery order for Nucala, an immunosuppressant biologic agent, represents one of numerous awards issued to the contractor by DLA's Medical Supply Chain division and reflects the company's consistent performance supporting Department of Defense medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FCFP4?
SPE2DR26FCFP4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FCFP4 worth?
The government has obligated $57,955 on SPE2DR26FCFP4.
Is contract SPE2DR26FCFP4 an order under another contract?
Yes. SPE2DR26FCFP4 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFP4 competed?
The extent of competition for SPE2DR26FCFP4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award